HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $70 price target.
GSK and Spero Therapeutics Announced Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr; Spero to Receive $66M Upfront Plus Potential Milestones Up to $375M
GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license agreement for Spero's late-stage antibiotic asset, tebipenem HBr.
